Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce key developments following the company’s annual and special meeting of shareholders, held in July. Bokhari reported that shareholders voted overwhelmingly in favor of all resolutions, including the election of all eight director nominees—two of whom are new to the board. Among the newly elected directors is The Honorable Cathy McMorris Rodgers, a veteran public servant with more than three decades of leadership experience. McMorris Rodgers represented Washington’s 5th Congressional District from 2004 to 2025 and previously served as Republican Leader in the Washington State House of Representatives—the first woman to hold that role. Bokhari described her as a people-first, mission-driven leader whose policy acumen and bipartisan leadership will bring tremendous value to Medicus Pharma during its next phase of growth. Also joining the board is Ajay Raju, a well-known attorney, venture capitalist, and entrepreneur. Raju is Chairman and CEO of Raju LLP, Managing Partner of 215 Capital, and Co-founder of Avstera Therapeutics, with leadership roles across 16 portfolio companies. His legal, financial, and strategic expertise further strengthens the company’s board as it advances clinical development and business expansion. In addition to governance updates, Bokhari revealed that Medicus has submitted a comprehensive briefing package to the U.S. Food and Drug Administration (FDA) requesting a Type C meeting. The company is seeking formal FDA feedback on its D-MNA (Dermal Methylnaltrexone) development program aimed at treating Basal Cell Carcinoma (BCC) of the skin. The proposed Phase 2 clinical trial (SKNJCT-003) will be a randomized, double-blind, placebo-controlled, multi-center study enrolling up to 60 participants. Subjects will be randomly assigned in equal numbers to receive either a Placebo, low-dose D-MNA, or high-dose D-MNA. The trial is designed to evaluate efficacy and safety outcomes, with the goal of accelerating the development of a novel topical therapy for one of the most common forms of skin cancer. With a strengthened leadership team and a clear regulatory strategy, Medicus Pharma is positioning itself for a pivotal year ahead in both corporate development and clinical advancement. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch #SkinCancer #BasalCellCarcinoma #BiotechNews #CancerResearch #UAEHealth #NonInvasiveTherapy #Doxorubicin #ClinicalTrials #HealthcareInnovation